I am an experienced Biotech executive with over 30 years in the industry, with roles in SME biotechnology companies and in big pharma. My last role was as SVP Research Immunology at Kymab (now a Sanofi company), where I led to development of the pharmacology and translational science function. My team successfully supported the preclinical development of KY1005 (SAR445229, Amlitelimab) and KY1044 (SAR445256, Alomfilimab) enabling their progression to clinical trials and well as developing a portfolio of molecules focussed in immunology-based therapeutics.
Prior to Kymab I was Director of Oncology Biology at MedImmune where my team was instrumental in describing the preclinical activity of the anti-PD-L1 antibody MedI4736 (Durvalumab) and developing a follow-on portfolio of novel therapeutics in immune-oncology.
I am a pharmacologist by training with a BSc in Pharmacology from Sunderland University